Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Paul Schloesser

Associate Editor

Cost-effectiveness watchdog ICER took a look at several different drugs approved for obesity and weight loss — and to them, there is a clear winner. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Vivus’ Qsymia beats out weight loss com­peti­tors in pric­ing watch­dog's lat­est cost-ef­fec­tive­ness analy­sis

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis